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Summary
Background.— Infusion of saline attenuates the decrease in renal function induced by radio-
graphic contrast agents among patients with chronic renal insufﬁciency.
Aim.— The Preventing Renal alteration in Coronary Disease (PRECORD) trial was a randomized
trial to assess the effect on renal function of saline infusion during and after coronary angiogra-angiography;
Prevention;
Randomized
controlled trial
phy in 201 patients without severe chronic renal insufﬁciency (serum creatinine < 140mol/L).
Methods.— All patients received standard oral hydration: 2000mL of tap water within the
24 hours after coronary angiography. Patients were randomized before the procedure to intra-
venous hydration (1000mL of 0.9% saline infusion) or no additional hydration. The infusion was
started in the catheterization laboratory and continued for 24 hours. The primary endpoint was
the change in calculated creatinine clearance between baseline and 24 hours after coronary
Abbreviations: CI, conﬁdence interval; CIN, contrast-induced acute nephropathy; PTCA, percutaneous transluminal coronary
angioplasty; SEM, standard error of the mean.
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angiography. The same ionic low osmolar radiographic contrast agent (ioxaglate) was used in
all patients.
Results.— Both groups had similar baseline characteristics, including age, serum creatinine, vol-
ume of contrast and proportion of patients undergoing ad hoc coronary angioplasty. The overall
decrease in serum creatinine clearance 24 hours after the procedure was —3.44 (0.68)mL/min.
The change in serum creatinine clearance 24 hours after the procedure was —2.81 (1.07)mL/min
in the infusion group vs —4.09 (0.91)mL/min in the control group (p = 0.38).
Conclusion.— Renal function is altered only slightly 24 hours after coronary angiography with
standard oral hydration alone and is not affected by saline infusion started at the beginning of
coronary angiography, even in patients with mild-to-moderate renal dysfunction.
© 2009 Elsevier Masson SAS. All rights reserved.
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Résumé
Prérequis.— La perfusion de sérum salé prévient la dégradation de la fonction rénale après
injection de produit de contraste chez les insufﬁsants rénaux chroniques.
Objectif.— L’étude Preventing Renal alteration in Coronary Disease (PRECORD) est un essai
thérapeutique randomisé évaluant l’effet protecteur de la perfusion de sérum salé au
cours d’une coronarographie chez 201 patients non insufﬁsants rénaux sévères (créatin-
inémie < 140mol/L).
Méthodes.— Tous les patients recevaient une hydratation orale de 2000mL d’eau du robinet
dans les 24 heures suivant la coronarographie. Les patients étaient randomisés avant l’examen
en deux groupes : un groupe recevant une hydratation supplémentaire par sérum salé 0,9 %
intraveineux 1000mL débuté en salle de cathétérisme et poursuivi pendant 24 heures, et un
groupe témoin sans hydratation supplémentaire. Le critère majeur était la diminution de la
clairance de la créatininémie calculée à 24 heures. Pendant la coronarographie, tous les patients
recevaient le même agent de contraste ionique à osmolarité basse (ioxaglate).
Résultats.— Les deux groupes étaient comparables à l’inclusion en ce qui concerne l’age, la
créatininémie, la quantité de produit de contraste et le nombre d’angioplastie. La diminution
moyenne de la clairance de la créatininémie observée à 24 heures était de —3,44 (0,68)mL/min.
Dans le groupe recevant la perfusion de sérum salé elle était de —2,81 (1,07)mL/min et dans
le groupe témoin de —4,09 (0,91)mL/min (p = 0,38).
Conclusion.— La fonction rénale n’est que modérément altérée après une coronarographie chez
les patients recevant une hydratation préventive per os. L’ajout d’une hydratation intraveineuse
en début de coronarographie n’entraîne pas de bénéﬁce signiﬁcatif chez des patients n’ayant
vère.
. Tous droits réservés.
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ackground
ontrast-induced acute nephropathy (CIN) is an important
omplication associated with the use of iodinated contrast
edia and accounts for a signiﬁcant number of cases of
ospital-acquired acute renal insufﬁciency [1]. CIN is typ-
cally deﬁned as an increase in serum creatinine occurring
ithin the ﬁrst 24 hours after contrast exposure and peaking
p to ﬁve days later [2]. CIN after percutaneous coro-
ary intervention has been shown to increase the risk of
eath signiﬁcantly, necessitating the evaluation of preven-
ive strategies [3].
Important risk factors are preexistent renal insuf-
ciency (particularly when associated with diabetes),
ontrast volume and dehydration [4—6]. In an unselected
opulation, the rate of acute decrease in renal func-
ion —deﬁned as a 25% increase in serum creatinine
oncentration— was 14.5% after percutaneous coronary
ntervention [7]. In patients without preexistent chronic
i
d
b
e
tenal insufﬁciency, an acute decrease in renal function
nduced by the administration of radiographic contrast
gents has been reported in up to 10% of patients
5,8—10].
Several prophylactic measures have been evaluated in
atients at high risk [11—17]. Previous studies suggest that
olume expansion using isotonic crystalloid, saline or bicar-
onate solution is an effective means of preventing a further
cute decrease in renal function induced by radiographic
ontrast agents in patients with chronic renal insufﬁciency
18—20].
No prospective randomized study has evaluated intra-
enous saline hydration in patients without preexistent
hronic renal insufﬁciency. The Preventing Renal alteration
n Coronary Disease (PRECORD) study was a prospective, ran-
omized, controlled, open-label study that investigated the
eneﬁt on renal function of saline infusion during and after
lective coronary angiography in patients without preexis-
ent chronic renal insufﬁciency.
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Methods
Patients
All consecutive patients between the ages of 18 and 80
years scheduled for elective coronary angiography, with
or without percutaneous transluminal coronary angioplasty
(PTCA), who had a baseline serum creatinine concentration
below 140mol/L (1.58mg/dL) between September 2000
and March 2001 were eligible for the study. Exclusion crite-
ria included New York Heart Association class IV congestive
heart failure, pregnancy, signiﬁcant valvular heart disease,
nonischaemic dilated cardiomyopathy, active cancer or any
life-threatening disease. The study protocol was approved
by the local ethics committee and all patients gave written
informed consent.
Study protocol
According to our hospital guidelines, all patients received
oral hydration with 2000mL of tap water in the 24 hours
after coronary angiography.
Patients were assigned treatment randomly upon arrival
in the catheterization laboratory by means of computer-
generated randomization. The randomization was stratiﬁed
according to sex and baseline creatinine level by a minimiza-
tion algorithm.
The infusion group received 1000mL of 0.9% saline infu-
sion, which was started at the beginning of the procedure
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Table 1 Baseline clinical and biochemical characteristics of t
Sex (male/female)
Age (years)
Baseline serum creatinine (mol/L)a
Baseline creatinine clearance (mL/min)b
Current smoker
Body mass index
Concomitant medication
Antihypertensive therapy
Antidiabetic therapy
Statin
Aspirin/clopidogrel
ACE inhibitor
Betablocker
Calcium channel antagonist
Diuretic agent
Peripheral artery disease
Indication for coronary angiography
First diagnosis
Unstable angina or NSTEMI
Postmyocardial infarction
Otherc
Values are number (%) or mean (standard error of the mean).
ACE: angiotensin-converting enzyme; NSTEMI: non-ST segment elevatio
a To convert values for serum creatinine from mol/L to mg/mL, mult
b Calculated with the Cockcroft and Gault formula from serum creatin
c Postcoronary artery bypass graft control, postpercutaneous translum763
nd continued for the next 24 hours. The control group
eceived no additional hydration.
Abdominal aortography was performed systematically
fter left ventriculography in the 20◦ left oblique anterior
rojection, to screen for the presence of renal artery steno-
is. By convention, an angiographically signiﬁcant lesion was
eﬁned as a greater than or equal to 50% luminal diameter
arrowing of a major renal artery [21].
An ionic low osmolar radiographic contrast agent (sodium
nd meglumine ioxaglate; Hexabrix® 320mg I/mL, Labo-
atoires Guerbet, Roissy CdG, France) was used for all
atients.
The primary endpoint was the change in serum creati-
ine clearance between baseline and 24 hours after coronary
ngiography.
Serum creatinine was measured in our hospital labora-
ory 12 to 24 hours before, and 24 hours after, coronary
ngiography. After discharge, one additional determination
f serum creatinine was performed in an external labo-
atory, three days after coronary angiography. Creatinine
learance was calculated with the Cockcroft and Gault for-
ula from serum creatinine concentration, weight, age and
ex [22].tatistical analysis
ased on a between-subject standard deviation of 24-hour
ercentage change in creatinine clearance of 15%, a trial
f 168 patients would have a power of more than 90% to
he study patients.
Infusion (n = 100) Control (n = 101)
80/20 82/19
62 (1) 62 (1)
86.7 (1.7) 85.6 (1.5)
85.7 (2.6) 85.8 (2.7)
16 (16) 22 (21.78)
26.8 (0.4) 26.7 (0.4)
44 (44) 37 (36.6)
16 (16) 12 (11.8)
45 (45) 43 (42.5)
79 (79) 78 (77.2)
29 (29) 29 (28.7)
60 (60) 59 (58.4)
32 (32) 31 (30.7)
21 (21) 20 (19.8)
12 (12) 13 (12.8)
65 (65) 80 (79.2)
9 (9) 5 (4.9)
6 (6) 5 (4.9)
20 (20) 11 (10.9)
n myocardial infarction.
iply by 0.0113.
ine concentration, weight, age and sex.
inal coronary angioplasty control, silent ischaemia.
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Table 2 Baseline cardiac catheterization, angiographic and procedural details.
Infusion (n = 100) Control (n = 101) p
Haemodynamic ﬁndings
Left ventricular end-diastolic pressure (mmHg) 16.8 (1.3) 13.9 (0.7) 0.05
Left ventricular ejection fraction (%) 61 (1.8) 59.8 (1.3) 0.58
Left ventricular end-diastolic volume (mL) 99.7 (3.8) 100.2 (3.2) 0.91
Coronary artery disease
No coronary artery disease 18 (18) 20 (19.8) 0.82
Atherosclerosis 15 (15) 13 (12.9) 0.78
One vessel 25 (25) 26 (25.7) 0.92
Two vessels 22 (22) 22 (21.8) 0.97
Three vessels 11 (11) 13 (12.9) 0.81
Left main coronary artery 9 (9) 6 (5.9) 0.69
Renal artery stenosis > 50% 9 (9) 4 (3.9) 0.60
PTCA performed during the procedure 34 (34) 31 (30.7) 0.67
Contrast agent dose (mL) 231.4 (7.8) 242.7 (8.6) 0.33
Patients without PTCA (mL) 207.8 (7.4) 215.8 (9.4) 0.51
Patients with PTCA (mL) 277.1 (15.1) 303.3 (12.9) 0.19
Dose of iodine (g/kg body weight) 0.99 (0.04) 1 (0.04) 0.85
Values are number (%) or mean (standard error of the mean).
PTCA: percutaneous transluminal coronary angioplasty.
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24 hours after coronary angiography. Corresponding values
in the control group were 85.8 (2.65)mL/min and 82
(2.72)mL/min. Serum creatinine clearance values for both
groups are presented in Fig. 1.
The mean overall decrease in serum creatinine clear-
ance 24 hours after the procedure was —3.44 (0.68)mL/min.
Changes in serum creatinine clearance 24 hours and three
days after coronary angiography in both groups are pre-
sented in Table 3.
The mean change in serum creatinine clearance 24 hours
after angiography in patients receiving antihypertensive
therapy was —1.98 (1.13)mL/min in the infusion groupetect, as signiﬁcant at the 5% level, an average difference
f 7.5% between the two treatments. We aimed to recruit
00 patients to allow for withdrawals and noncompliance.
All analyses were done according to a prespeciﬁed sta-
istical analysis plan by intention to treat. The analysis
ompared creatinine clearance value at 24 hours between
he two treatments, with adjustment for the baseline val-
es by analysis of covariance. Analyses were performed
n R software. Statistical analyses ignoring these base-
ine results produced similar results. All p-values were
wo-tailed; 95% conﬁdence intervals (CIs) were calculated
or differences within and between treatment groups. All
esults are reported as means (SEM).
esults
etween September 2000 and March 2001, 201 patients
ere assigned randomly to the infusion group (100 patients)
r the control group (101 patients) in our department;
heir baseline characteristics are shown in Table 1. The
wo groups were similar with respect to age, baseline
reatinine clearance, body mass index and concomitant
edication. Cardiac catheterization, angiographic and pro-
edural details before any oral or intravenous hydration are
hown in Table 2.
Serum creatinine 24 hours after the procedure was
easured in 97 patients from the infusion group and 96
atients from the control group. Serum creatinine three
ays after the procedure was measured in 74 patients from
he infusion group and 85 patients from the control group. In
he infusion group, mean serum creatinine clearance varied
rom 85.7 (2.58)mL/min at baseline to 82.5 (2.62)mL/min
Figure 1. Serum creatinine clearance at baseline, 24 hours and
three days after angiography. Error bars are the standard error of
the mean.
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Table 3 Changes in serum creatinine clearance 24 hours and 3 days after angiography, according to treatment group.
Change in creatinine clearance (mL/min)a Treatment effect (95% CI) p
Infusion Control
24 hours after angiography −2.81 (1.07) −4.09 (0.91) 1.28 (−1.49, 4.05) 0.38
3 days after angiography −4.76 (1.25) −4.73 (1.21) −0.03 (−3.46, 3.39) 0.93
CI: conﬁdence interval.
a Values are mean (standard error of the mean).
Table 4 Comparison of serum creatinine clearance before and 24 hours after angiography in the different quartiles,
according to treatment group.
Creatinine clearance (mL/min) p
Infusion Control
1st quartile (n = 24) (n = 24)
Before angiography 54.7 (1.8) 57.2 (1.4)
24 hours after angiography 54.4 (2.5) 54.6 (1.3)
Change −0.4 (1.4) −2.6 (1.2) 0.23
2nd quartile (n = 24) (n = 24)
Before angiography 73.9 (0.8) 73.5 (1.0)
24 hours after angiography 72.2 (1.4) 71 (1.7)
Change −1.7 (1.0) −2.5 (1.3) 0.62
3rd quartile (n = 24) (n = 24)
Before angiography 91.2 (1.6) 89.8 (1.3)
24 hours after angiography 89 (2.7) 86.5 (2.5)
Change −2.1 (2.3) −3.3 (2.0) 0.70
4th quartile (n = 25) (n = 24)
Before angiography 120.2 (2.8) 123.7 (4.0)
24 hours after angiography 113.3 (3.9) 115.8 (4.8)
Change −6.9 (3.0) −7.9 (2.4) 0.79
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(n = 44) vs —4.12 (1.58)mL/min in the control group (n = 37).
The mean change in serum creatinine clearance 24 hours
after angiography in patients receiving antidiabetic therapy
was —3.31 (3.2)mL/min in the infusion group (n = 16) vs 0.88
(3.88)mL/min in the control group (n = 12).
A comparison of serum creatinine clearance before and
24 hours after angiography in the different quartiles is shown
in Table 4. Twenty-four hours after the procedure, an
increase in serum creatinine of more than 25% occurred in six
patients (6%) in the infusion group and four patients (3.9%)
in the control group. Three days after the procedure, an
increase in serum creatinine of more than 25% occurred in
ﬁve patients (5%) in the infusion group and seven patients
(6.9%) in the control group.
Angiographically signiﬁcant renal artery stenosis was
found in 13 patients (nine in the infusion group and four in
the control group); their mean baseline creatinine clearance
of 79.05 (7.04)mL/min did not differ signiﬁcantly from that
of the overall population (85.76 [1.84]mL/min; p = 0.38). No
patient required dialysis or died within 30 days after the
procedure.
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hanges in serum creatinine clearance 24 hours after
oronary angiography were moderate with standard oral
ydration in patients without severe renal dysfunction. We
ound no beneﬁt of additional intravenous hydration started
t the beginning of coronary angiography in our popula-
ion.
The PRECORD study is the ﬁrst prospective, randomized
rial evaluating intravenous hydration in patients sched-
led for elective coronary angiography without preexistent
hronic renal insufﬁciency. It is also the ﬁrst study using
tandardized oral hydration for all patients. As expected
rom studies reported previously, the incidence of acute
ecrease in renal function was low in our population [23].
n previous studies an acute decline in renal function was
enerally deﬁned as a rise in serum creatinine of more than
5% within three days of administration of radiographic con-
rast agents. We used calculated creatinine clearance from
he formula of Cockcroft and Gault, which is a more accu-
ate means of estimating glomerular ﬁltration rate than
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sing serum creatinine concentration alone [4,24]. On inclu-
ion, all patients had serum creatinine concentrations below
40mol/L (1.58mg/dL), which was considered to reﬂect
ormal renal function. The second quartile had a serum cre-
tinine clearance below 90mL/min, which indicates mild
enal dysfunction, and the ﬁrst quartile had a serum creati-
ine clearance below 60mL/min, which indicates moderate
enal insufﬁciency. In these quartiles, the change in serum
reatinine clearance 24 hours after coronary angiography did
ot differ signiﬁcantly between groups. In accordance with
revious studies we found a 5% incidence of signiﬁcant acute
ecline in renal function (deﬁned as a rise in serum creati-
ine greater than 25% above the baseline) at 24 hours and
6% incidence at three days, with no difference between
nfusion and control groups.
Our study compared oral hydration with a combination
f oral and intravenous hydration. Previous studies used
.45% saline infusion at a rate of 1mL per kilogram of body
eight per hour, beginning 12 hours before angiography. In
randomized trial, hydration using 0.9% saline infusion has
een shown to be more effective than 0.45% saline infu-
ion in the prevention of acute decline in renal function
fter coronary angiography, even without precatheteriza-
ion hydration [23]. The combination of oral and intravenous
ydration has been shown to be effective in preventing
cute changes in renal function in patients with mild-to-
oderate renal dysfunction in a prospective, randomized
rial [25]. Adequate intravenous volume expansion with
sotonic crystalloid (1—1.5mL/kg per hour) for 3—12 hours
efore the administration of iodinated contrast media and
ontinued for 6—24 hours afterwards is a well established
nd recommended method for reducing the risk of CIN in
atients with chronic renal failure [26]. In the present study,
aline infusion was started only at the beginning of the
rocedure, and not several hours before, which decreases
he potential protective effect of intravenous hydration on
IN. Therefore we cannot exclude a beneﬁt of intravenous
ydration started 3—12 hours before the procedure in our
opulation. The volume of saline infusion and water intake
as not adjusted to body weight or clinical conditions.
ll patients received 2000mL of tap water after coronary
ngiography and the infusion group received 1000mL of 0.9%
aline infusion started at the beginning of coronary angiog-
aphy. We did not observe any hydration-induced pulmonary
edema even in patients with impaired left ventricular func-
ion.
In our population, baseline-calculated serum creatinine
learance was at the 75th percentile according to population
ge- and sex-based standards [27]. We measured serum cre-
tinine 24 hours and three days after coronary angiography
o avoid underestimating the occurrence of radiocontrast-
nduced decrease in renal function [28]. Most patients were
ischarged within 48 hours after coronary angiography. The
hange in serum creatinine clearance 24 hours after coro-
ary angiography was our major endpoint because serum
reatinine was measured in the same hospital laboratory as
aseline serum creatinine. Serum creatinine clearance three
ays after coronary angiography would have been more
ensitive but it was measured in various external labora-
ories, leading to greater measurement variability. Absolute
hanges in creatinine clearance three days after coronary
ngiography were similar in both groups.
RD. Angoulvant et al.
Our study excluded patients with preexistent chronic
enal insufﬁciency diagnosed on the basis of baseline serum
reatinine and/or past medical history. We screened for
he presence of renal artery stenosis to evaluate the inci-
ence of potential ischaemic renal disease and its inﬂuence
n renal function after coronary angiography. We found a
.5% incidence of angiographically signiﬁcant renal artery
tenosis in our population, which is in keeping with previ-
usly reported studies [21,29]; baseline creatinine clearance
nd change in creatinine clearance 24 hours after coro-
ary angiography did not differ signiﬁcantly between these
atients and the rest of our population.
All patients received the same low osmolar ionic radio-
ontrast media that is preferred over nonionic contrast
edia in coronary angiography [30]. The volume of radio-
ontrast media and the iodine dose administered were
oderate and similar to those in a recent study in compa-
able patient cohorts [23]. Previous studies have shown that
he use of ionic radiographic contrast agent is not associated
ith a higher incidence of acute decrease in renal function
ompared with nonionic contrast agent [31].
Renal protection in coronary patients is a major concern
ecause altered renal function in essential hypertension,
dvanced heart failure and after a myocardial infarction is
ssociated with higher cardiovascular morbidity and mortal-
ty [32—34]. The expanding use of diagnostic and therapeutic
oronary angiographymakes it important to establish recom-
endations for nephroprotection, even in patients without
reexistent chronic renal insufﬁciency. Acute radiocontrast
ephropathy is not the only potential cause of renal impair-
ent after coronary angiography. Cholesterol embolization
nduced by the introduction of catheters is probably under-
eported, but generally presents with a progressive decline
n renal function a few weeks rather than a few days after
he procedure [35]. There is no reason to expect that oral or
ntravenous hydration would prevent this late complication
f coronary angiography.
onclusion
e found no evidence of a beneﬁt of intravenous hydra-
ion with 0.9% saline started at the beginning of coronary
ngiography over standard oral hydration with tap water
fter coronary angiography on renal function in patients with
ormal or mild-to-moderate renal dysfunction.
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